Explore our blogs on various markets

Generative AI is transforming the way pharmaceutical companies operate. It helps teams discover drugs faster, write documents quicker, and find insights in huge amounts of data. Instead of doing everything manually, experts can now use GenAI to save time and focus on what matters most—patient care and innovation....

Summary:. Roche, one of the world’s biggest drugmakers, is thinking about selling its medicines directly to patients in the United States. The company’s CEO, Thomas Schinecker, said this plan could help reduce the high cost of prescription drugs in the country...

Roivant Sciences is developing brepocitinib, a new oral drug that blocks both TYK2 and JAK1. These proteins play a key role in autoimmune diseases like dermatomyositis and lupus. . Brepocitinib targets several harmful signals in the body, not just one, which may make it more effective than older treatments...

Summary. Roche has officially initiated the global rollout of Lunsumio® (mosunetuzumab) for the treatment of adult patients with third-line and beyond relapsed or refractory follicular lymphoma (FL). The fixed-duration, off-the-shelf, T-cell engaging bispecific antibody has already been commercially used in over 2,400 patients, according to company data, with significant adoption across major oncology markets....

Zomedica Pharmaceuticals has released a new and improved canine cortisol assay for its TRUFORMA point-of-care diagnostic platform. . The assay allows veterinarians to diagnose Cushing’s syndrome and Addison’s disease within minutes, using a simple in-clinic process. . Previously, such diagnoses required shipping blood samples to external labs and waiting one or two days for results...

Discover the top 5 generative AI tools transforming drug discovery with faster molecule design, target prediction, and real-world pharma applications.. Generative AI has almost transformed how drug discovery works today. In the last five years, it has gone from being a research experiment to a practical tool used by biotech firms and pharmaceutical companies around the world. ...

The market for generic immunology drugs in the Asia-Pacific (APAC) region is witnessing rapid expansion, driven by increasing healthcare access, rising chronic disease prevalence, and cost-containment measures by governments. . As more biologics go off-patent, pharma companies are moving quickly to introduce affordable generic and biosimilar alternatives across key APAC markets.. If you are planning to enter or expand in this space, pricing is one of the most critical levers for success...

In 2025, the pharmaceutical industry is seeing major changes in drug development, pricing, and delivery. AI is speeding up R&D, GLP-1 drugs are redefining obesity treatment, and precision medicine is becoming standard. . This guide breaks down the top trends shaping pharma this year, with real examples and their impact on healthcare and business....

Artificial Intelligence (AI) is changing modern healthcare by helping doctors make faster, smarter decisions. From diagnosing diseases to personalizing treatments and reducing paperwork, AI is making care more accurate and efficient. . With the global AI healthcare market expected to reach nearly $96 billion by 2033, it's clear that AI is no longer just a future trend—it’s a key part of today’s medical systems. ...

AI is changing how we discover new medicines. Instead of testing each idea in a lab, AI studies massive medical data to quickly find the most promising drug candidates. . This speeds up research, lowers costs, and improves success rates...